Coger: Distributeur de reactifs de laboratoire
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
|
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
|
Stock épuisé.
En rupture de stock
|
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
Cabozantinib
50 mg
photos non contractuelles
Détails Produit
Product description: Chemical. CAS: 849217-68-1. Formula: C28H24FN3O5. MW: 501.5. Cabozantinib is a potent multi-targeted receptor tyrosine kinase (RTK) inhibitor of endothelial growth factor receptor 2 (VEGFR2) (IC50=0.035nM), the hepatocyte growth factor receptor c-Met (IC50=1.3nM), AXL (IC50=7nM), fms like tyrosine kinase 3 (FLT3) (IC50=11.3nM), mast/stem cell growth factor (KIT) (IC50=4.6nM), RET (IC50=5.2nM), tyrosine-protein kinase receptor (TIE-2) (IC50=14.3nM) and RON (IC50=124nM). Cabozantinib reduces cell proliferation and vascular density. It also induces apoptosis and intratumoral hypoxia. Cabozantinib exhibits dose-related tumor growth inhibition, tumor regression, angiogenesis and/or metastasis inhibition in a broad range of preclinical tumor models. The anticancer compound cabozantinib has undergone clinical trial in a broad number of cancers, including thyroid carcinoma, prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma and glioblastoma.
|
Alerte
Veuillez saisir les champs obligatoires! |
